% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • leverjesus leverjesus May 19, 2011 5:24 PM Flag

    Euro-Biotech Forum

    TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Regulatory News:

    EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm: EPCT) announced today that Jack Talley, President and Chief Executive Officer, will be presenting at the 18th Annual Euro-Biotech Forum at the Hilton Arc de Triomphe in Paris, France on May 24th 2011 at 1:45 pm local time. Mr. Talley will present a company overview.

    About EpiCept Corporation

    EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Company's lead product is Ceplene®, approved in the European Union and several other countries for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. In the United States, a pivotal trial is scheduled to commence in 2011. The Company has two other oncology drug candidates currently in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors. The Company's pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Would be sufficient for investors if they get RESULTS in written form. People already left the room when this Talley started stuttering with his fuzzy speculations. It's my experience that the share price always dropped after his attempts of a “presentation”. The only result of such Talley's activities is wasting the stockholder money in luxury hotels.

1.76-0.04(-2.22%)11:09 AMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.